The effectiveness of ischemic preconditioning on myocardial protection and comparison with K(+) cardioplegia.
The purpose of this study is to investigate the effects of ischemic preconditioning on myocardial protection and to compare this method to K(+) crystalloid cardioplegia. Langendorff perfused isolated working rat hearts were used in the following groups. After 20 min of stabilisation, 30 hearts were divided into three groups. In group I (control, n=10), hearts were arrested with cold (+4 degrees C) Krebs-Henseleit (K-H) solution, in group II (cardioplegia, n=10) hearts were arrested with cold K(+) cardioplegia solution, and in group III (preconditioning, n=10) hearts were subjected to 5 min normothermic ischemia followed by 5 min reperfusion then arrested with cold K-H solution. All hearts were subjected to 30 min of global ischemia (24 degrees C) and 40 min of reperfusion. Hemodynamic measurements were performed with a left ventricular latex balloon using a data acquisition system. Creatine kinase (CK-MB) washout and Troponin I (cTnI) levels were determined from the coronary effluents. There was no significant difference among the three groups in any of the parameters (hemodynamic and biochemical) measured at the end of stabilisation period. During reperfusion, functional recovery and coronary flow were significantly improved in K(+) cardioplegia and preconditioned groups compared with control group. CK-MB washout and cTnI levels were significantly lower in groups II and III compared with group I at the reperfusion. However no significant difference was observed between K(+) cardioplegia and preconditioned groups among biochemical and hemodynamic parameters and coronary flow at the post-ischemic period. In conclusion, ischemic preconditioning is as effective as K(+) cardioplegia on myocardial protection and recovery of myocardial function during reperfusion.
Dernek
S
S
Departments of Cardiovascular Surgery and Biochemistry, Medical Faculty, Osmangazi University, Eskişehir, Turkey. sdernek@ogu.edu.tr
Ikizler
M
M
Uyguç
O
O
Alatas
O
O
Kural
T
T
D000818:Animals; D002314:Cardioplegic Solutions; D003326:Coronary Circulation; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form; D005947:Glucose; D006324:Heart Arrest, Induced / Q000379:methods*; D006439:Hemodynamics; D019194:Ischemic Preconditioning; D007527:Isoenzymes; D008297:Male; D009206:Myocardium / Q000378:metabolism; D011188:Potassium; D051381:Rats; D017207:Rats, Sprague-Dawley; D014325:Tromethamine; D019210:Troponin I / Q000378:metabolism
D002314:Cardioplegic Solutions; D007527:Isoenzymes; C074097:Krebs-Henseleit solution; D019210:Troponin I; D014325:Tromethamine; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form; D005947:Glucose; D011188:Potassium